Management of Magnesium Supplementation in Bartter Syndrome
Introduction to Magnesium Supplementation
- The European Rare Kidney Disease Reference Network recommends targeting a magnesium plasma level >0.6 mmol/L (>1.5 mg/dL) for patients with Bartter syndrome who require magnesium supplementation, using organic magnesium salts (aspartate, citrate, lactate) divided into as many doses as possible throughout the day 1, 2, 3, 4.
Choosing the Right Magnesium Form
- Organic magnesium salts (aspartate, citrate, lactate) should be used because they have higher bioavailability compared to magnesium oxide or hydroxide, which is crucial for patients with Bartter syndrome who experience continuous urinary magnesium loss 1, 2, 3, 4.
Target Magnesium Levels
- The target magnesium plasma level should be >0.6 mmol/L (>1.5 mg/dL), although the exact target for Bartter syndrome is not well-defined, this level seems reasonable based on the consensus of the European Rare Kidney Disease Reference Network 1, 2, 3, 4.
Dosing Strategy
- Magnesium supplementation should be divided into as many doses as possible throughout the day to mimic continuous supplementation, as urinary electrolyte loss is continuous 1, 2, 3, 4, 5.
Importance of Magnesium Correction in Potassium Management
- Hypomagnesemia is the most common cause of refractory hypokalemia and should be corrected before or simultaneously with potassium supplementation, as magnesium deficiency leads to dysfunction of the potassium transport system and increased renal potassium excretion 6.
- Approximately 40% of hypokalemic patients have concurrent hypomagnesemia, and in Bartter syndrome type 3 (CLCNKB mutation), hypomagnesemia is very common and requires special attention 1, 2, 3, 4, 6.
Monitoring
- Regularly check magnesium serum levels along with other electrolytes (potassium, sodium, chloride, bicarbonate), renal function, and PTH, with monitoring frequencies depending on patient age and stability of therapy 1, 2, 5.
- Monitoring frequencies: